Unlocking the key to an effective vaccine

July 02, 2020

A recent study by Monash University has looked at the role plasma cells and their longevity play in the effectiveness of vaccines in the body and suggests that components within vaccine design are the key.

In the wake of the COVID-19 outbreak, a lot of research is focussed on developing a vaccine. For a vaccine to be successful, it has to do two things. First, it must signal the body to generate a lot of plasma cells making anti-virus antibodies. Second, these plasma cells have to live and produce antibodies for years or even decades for the vaccination to succeed. However, the reality is that most of them only survive a few days.

A recent study published in the journal Immunological Reviews, led by Professor David Tarlinton from Monash Central Clinical School's Immune Memory Laboratory, suggests that components within vaccines can play a major role in aiding the lifespan of individual plasma cells. Understanding the processes involved in long-lived plasma cell formation will open up ways of making vaccines more effective.

"One of the difficulties in designing an effective vaccine is that it is unclear exactly what determines how long a single plasma cell will survive. We only have a limited understanding of what might be special about those plasma cells that survive for the longer periods, and what it is in their development that tells them that they, specifically, should survive," said Professor Tarlinton.

The paper takes a further conceptual step, and outlines there is also likely competition between plasma cells for survival cues, such that there could be a 'survival of the fittest' bent to long-term antibody-based immunity.

Monash University research fellow, Dr Marcus Robinson in Professor Tarlinton's lab, says the paper outlines a framework that can be used to determine the individual signals that lead to long-lived antibody responses by the plasma cells.

"It is exciting to know we are on the cusp of understanding what is a complicated sequence of events, and that this understanding might feed into vaccine design in the near future", he said.
-end-
Read the full paper in Immunological Reviews titled: "How intrinsic and extrinsic regulators of plasma cell survival might intersect for durable humoral immunity". 2020 vol.296. DOI: 10.1111/imr.12895

Media enquiries

Monash media
+61 (0) 425 725 836
media@monash.edu

Monash University

Related Vaccines Articles from Brightsurf:

Comprehensive safety testing of COVID-19 vaccines based on experience with prior vaccines
'The urgent need for COVID-19 vaccines must be balanced with the imperative of ensuring safety and public confidence in vaccines by following the established clinical safety testing protocols throughout vaccine development, including both pre- and post-deployment,' write David M.

Safety of HPV vaccines in males
A new analysis published in the British Journal of Clinical Pharmacology shows that HPV vaccines are safe and well tolerated in the male population, and the side effects that may occur after immunization are similar in both sexes.

Model could improve design of vaccines, immunotherapies
Researchers have discovered a general property for understanding how immune cell receptors sense and respond to microbial signals, which could lead to more effective vaccines for both existing and novel viruses.

Better vaccines are in our blood
Red blood cells don't just shuttle oxygen from our lungs to our organs: they also help the body fight off infections by capturing pathogens in the blood and presenting them to immune cells in the spleen.

Challenges in evaluating SARS-CoV-2 vaccines
With more than 140 SARS-CoV-2 vaccines in development, the race is on for a successful candidate to help prevent COVID-19.

Designing vaccines from artificial proteins
EPFL scientists have developed a new computational approach to create artificial proteins, which showed promising results in vivo as functional vaccines.

Misinformation on vaccines readily available online
Parents researching childhood vaccinations online are likely to encounter significant levels of negative information, researchers at the University of Otago, Wellington, have found.

Battle with the cancer: New avenues from childhood vaccines
A new research from the University of Helsinki showed for the first time how the pre-immunization acquired through common childhood vaccines can be used to enhance therapeutic cancer treatment.

Personalized cancer vaccines
The only therapeutic cancer vaccine available on the market has so far showed very limited efficacy in clinical trials.

Doubts raised about effectiveness of HPV vaccines
A new analysis of the clinical trials of HPV vaccines to prevent cervical cancer raises doubts about the vaccines' effectiveness.

Read More: Vaccines News and Vaccines Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.